Recovery sustains, margin pressure looms near-term
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade A
Hit Q2 guidance: 32% YoY revenue (prior ₹150 Cr target exceeded), 17.68% EBITDA margin (within 15%-18% range). Long-term targets reaffirmed. No prior misses cited.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong Q2 recovery (32% revenue, 69% PAT growth) validates demand rebound post-inventory normalization and exceeds prior ₹150 Cr quarterly run-rate target. However, sequential margin compression (-11.7% PAT QoQ despite 14% revenue growth) flags near-term cost pressure from new facility ramp, working capital drag, and input inflation. Long-term margin guide (15%-18%) reaffirmed but Europe/US catalysts deferred to 2028-2030. Hold until Phase II utilization ramp and cost normalization materialize.
₹158.7 Cr
Revenue · +32% YoY₹16.2 Cr
Reported PAT · +68.8% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
Q2 revenue ₹158.71 Cr, 32% YoY growth
METDelivered ₹158.7 Cr, 32% YoY — matches exactly
EBITDA ₹28.06 Cr with 17.68% margin
METOPM 17.7% × ₹158.7 Cr = ₹28.08 Cr EBITDA — matches
PAT ₹16.25 Cr, 69% YoY growth
METDelivered ₹16.2 Cr, 68.8% YoY — matches within rounding
Q2 growth driven by volumes, not prices
METAnalyst pressed; mgmt confirmed substantial part from volumes
EBITDA margin within 15%-18% guided range
MET17.68% delivered; at high end of guide, corroborates
30%-40% utilization at Phase II over next 2-3 quarters
METManagement stated explicitly; concrete facility + plan
Sequential PAT decline (-11.7%) despite 14% QoQ revenue growth
METCost inflation, depreciation, inventory carrying costs explain margin compression
Earnings quality
What changed since the last call
Phase II facility now operational
NewCommission completed Sep 2026. Provides incremental capacity; utilization ramp to 30%-40% planned. Near-term margin pressure expected from depreciation + fixed cost absorption.
Europe timeline slips; customer slower than planned
DowngradePrior target ₹50-60 Cr from Europe this year likely missed. Mgmt now guides critical mass to 2028-2030. Customer onboarding takes 2-3 yrs post-regulatory approval.
Margin guide maintained, not upgraded
NeutralDespite 32% YoY growth delivery, mgmt reaffirmed 15%-18% long-term target, not higher. Implies cost base rising in line with or above revenue during facility ramp phase.
Inventory strategy from manufacturing-to-order to manufacturing-to-stock
NewShifted ~1 year ago. Inventory now ₹118 Cr (Sep) vs ₹70 Cr (March). Expected to normalize over 2-3 qtrs as facility ramps and demand stabilizes.
The Q&A
Analysts probed hard on margin sustainability (Rohit/PMS, Raghuram/Bestpals), price realization (Ishan/Fort), Europe timeline (Dhwani/Turtle), competitive moat (Raghuram/Bestpals). Mgmt held margins at 15%-18% despite growth, defended cost inflation as transient, acknowledged Europe slower than hoped but realistic on 2028-2030 timeline. Tone was defensive on margins but transparent on challenges. No major concessions made.
Cost inflation & margin pressure — Dhwani Desai, Turtle Capital
AnsweredAbout 50% of new facility staffing in place; operating costs will increase; margin pressure expected near-term. Anticipate easing as utilization ramps.
Price sustainability — Ishan Thakkar, Fort Capital
AnsweredSubstantial part from volumes. Fluralaner prices down; will likely see further erosion next 6 months, then stabilization. Pricing pressure ongoing.
Depreciation & finance costs — Rahul Jain, Credence Wealth
AnsweredAnticipate further depreciation of ~₹3 Cr. Finance costs capped at 20% above current level. Capitalizing assets as deployed.
Phase II utilization ramp — Rohit, PMS
PartialCannot estimate FY28 precisely due to market/demand variability. Market performing well; facility occupied with existing + new products. Phase I already contributing materially.
Regulated market margins — Raghuram Kuchi, Bestpals Research
Answered15%-18% target for unregulated; 18%-22% for regulated. Currently ~95% animal health (mostly unregulated). Regulated markets slower to develop.
Europe/US revenue timing — Raghuram Kuchi, Bestpals Research
PartialToo early to estimate market share. Objective is register as many products as possible. Lead time 2-3 yrs post-approval. Expect critical mass 2028-2030.
Gross margin trend — Rahul Jain, Credence Wealth
AnsweredLong-term 50%-55% range. Currently at upper end. Can move up/down couple percentage points as mix evolves.
Guidance
FY27 trajectory on track; quarterly stabilization at ₹150 Cr+ achieved
HighQ2 ₹158.7 Cr exceeds prior Q4 FY26 target. Market strong. FY27 full-year trajectory assumed stable.
Long-term EBITDA margins 15%-18% reaffirmed; 18%-22% target for regulated markets
MediumQ2 delivered 17.68%, within range. Near-term pressure from depreciation (₹3 Cr more ahead), costs, inventory. Timing of easing unclear.
Phase II capex ₹220 Cr total; H1 spent ₹44.05 Cr. Capex to tail off as completion nears.
HighFacility operational (Sep 2026). Remaining capex likely modest finishing touches. No new major capex announced.
Risks the call surfaced
Regulatory approval risk
HighUS business entirely contingent on customer filing (Dec 2026) and subsequent audit. First-time audit could flag observations. Europe already slow (9 of 17 approvals); critical mass pushed to 2028-2030.
Working capital / capex intensity
MediumInventories jumped from ₹70.28 Cr to ₹118.38 Cr (H1). Strategy shift to manufacturing-to-stock + Gulf War fear spike. Capex ₹44 Cr in H1 consuming cash. Net debt ₹122 Cr (vs ₹108 Cr prior year).
Customer concentration
MediumAnimal health APIs is unregulated market with high concentration. Loss of a large customer or product could materially impact revenue.
Margin compression from new facility ramp
MediumPhase II adds ₹3 Cr+ annual depreciation; finance costs +20% from prior level. At 30%-40% utilization ramp, fixed costs pressure margins. Sequential PAT -11.7% QoQ on 14% revenue growth flags near-term compression.
Commodity & input cost volatility
LowFuel and logistics costs elevated from Gulf War situation; distribution costs nearly doubled. Raw material costs sensitive to global availability. Rupee weakness temporarily aided forex.
Management
Score 7/10. Transparent on challenges (cost inflation, inventory, margin pressure, timeline slips). Clear on strategy (Phase II ramp, regulated market positioning). Some evasion on market size / competitive positioning (asked twice on EU/US addressable market; got 'too early' response). Hit Q2 guidance (32% YoY revenue, 17.68% EBITDA margin within 15%-18% range). Phase II facility on schedule (Sep 2026). Regulatory progress on track (9 of 17 EU filings approved, US veterinary master files filed). No major misses cited.
1 · Q3-Q4 FY27
Inventory normalization; working capital pressure eases
2 · Dec 2026
US customer filings complete; inspection may trigger
3 · Dec 2027
Europe regulatory approvals target (all 17 filings); customer onboarding
Hold until Phase II utilization ramp and cost normalization materialize.
Informational and educational content only. Not investment advice.